ReviewNature reviews. Endocrinology2014
Novel metabolic biomarkers of cardiovascular disease.
Review in Nature reviews. Endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 101 citations in OpenAlex.
- Cholesterol efflux capacity, HDL cholesterol, and risk of coronary heart disease: a nested case-control study in men.Journal of lipid research · 2019Trial
- Trial
- Reversible Pulmonary Hypertension in CblC Deficiency (MMACHC c.80 A>G): long-term outcomes of metabolic and PH-targeted therapy.Pediatric research · 2026Article
- Pathophysiology of homocysteine: insights into ion channel dysfunction.Pflugers Archiv : European journal of physiology · 2026Review
- Association of age at menopause with cardiovascular disease and mortality:insights from NHANES and a clinical cohort.Frontiers in cardiovascular medicine · 2026Article
- Novel cardiac biomarkers and multiple-marker approach in the early detection, prognosis, and risk stratification of cardiac diseases.World journal of cardiology · 2025Review
- Metabolic theory of preeclampsia: implications for maternal cardiovascular health.American journal of physiology. Heart and circulatory physiology · 2024Review
- A multiplexed immunochemical microarray for the determination of cardiovascular disease biomarkers.Mikrochimica acta · 2023Article
- FLUXestimator: a webserver for predicting metabolic flux and variations using transcriptomics data.Nucleic acids research · 2023Article
- Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions.Cardiovascular diabetology · 2023Review
- CaBiomolecules · 2023Article
- No causal effect of genetically determined circulating homocysteine levels on psoriasis in the European population: evidence from a Mendelian randomization study.Frontiers in immunology · 2023Article
- Choline diet improves serum lipid parameters and alters egg composition in breeder ducks.Veterinary medicine and science · 2022Article
- Plasma proteome profiling combined with clinical and genetic features reveals the pathophysiological characteristics of β-thalassemia.iScience · 2022Article
- Lipoprotein-associated phospholipase AProceedings of the National Academy of Sciences of the United States of America · 2022Article
- GDF15 and Cardiac Cells: Current Concepts and New Insights.International journal of molecular sciences · 2021Review
- Review
- Identification of Inflammation-Related Biomarker Lp-PLA2 for Patients With COPD by Comprehensive Analysis.Frontiers in immunology · 2021Article
- Plasma Proteomes Can Be Reidentifiable and Potentially Contain Personally Sensitive and Incidental Findings.Molecular & cellular proteomics : MCP · 2021Article
- Identification of Key Exosome Gene Signature in Mediating Coronary Heart Disease by Weighted Gene Correlation Network Analysis.BioMed research international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary heart disease (CHD) accounts for one in every six deaths in US individuals. Great advances have been made in identifying important risk factors for CHD, such as hypertension, diabetes mellitus, smoking and hypercholesterolaemia, which have led to major developments in therapy. In particular, statins represent one of the greatest successes in the prevention of CHD. While these standard risk factors are important, an obvious opportunity exists to take advantage of ongoing scientific research to better risk-stratify individuals and to identify new treatment targets. In this Review, we summarize ongoing scientific research in a number of metabolic molecules or features, including lipoproteins, homocysteine, calcium metabolism and glycaemic markers. We evaluate the current state of the research and the strength of evidence supporting each emerging biomarker. We also discuss whether the associations with CHD are strong and consistent enough to improve current risk stratification metrics, and whether these markers enhance our understanding of the underlying biology of CHD and thus point towards new treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.